Children’s Hospital of Philadelphia appoints leukemia specialist as section chief
Click Here to Manage Email Alerts
Sarah K. Tasian, MD, has been appointed chief of the section of hematologic malignancies within the division of oncology at Children’s Hospital of Philadelphia.
Tasian, a pediatric oncologist and physician scientist at Children’s Hospital of Philadelphia (CHOP) and University of Pennsylvania School of Medicine, is recognized for her expertise in acute lymphoblastic leukemia and acute myeloid leukemia. Her research has focused on testing kinase inhibitors and chimeric antigen receptor T-cell therapies for subsets of children with high-risk ALL or AML.
“She is uniquely suited for this new role and, as a current CHOP faculty member, has established herself as a world leader in basic, translational and clinical research in leukemia, with a focus on developing new precision medicine therapies and immunotherapies for high-risk and relapsed acute leukemias,” Stephen Hunger, MD, chief of the division of oncology at CHOP, said in a press release. “She holds multiple NIH grants, is an outstanding teacher and educator and a consummate physician. I look forward to working closely with her in this new role.”
Tasian will succeed Richard Aplenc, MD, PhD, MSCE, who served as chief of the section of hematologic malignancies for 13 years.
Click Here to Manage Email Alerts